IGF-1 DES
Also known as: Des(1-3) IGF-1, IGF-1 Des 1-3
Truncated IGF-1 Analog | Localized Muscle Growth
Overview
IGF-1 DES (Des(1-3) IGF-1) is a truncated analog of insulin-like growth factor-1, missing the first three N-terminal amino acids. This structural modification eliminates binding to IGF binding proteins (IGFBPs), meaning 100% of the peptide is bioactive rather than being sequestered in circulation. The result is approximately 10x greater potency than native IGF-1, but with an extremely short half-life of 20-30 minutes. This short duration of action is considered a feature rather than a limitation -- it allows for site-specific injection into target muscles immediately post-workout, promoting localized growth with reduced systemic exposure.
Key benefits
- Approximately 10x more potent than native IGF-1
- 100% bioactive -- does not bind to IGF binding proteins
- Extremely short half-life enables localized, site-specific action
- Promotes satellite cell activation for muscle hyperplasia
- Minimal systemic exposure compared to IGF-1 LR3
Mechanism of action
IGF-1 DES activates the IGF-1 receptor (IGF-1R) and downstream PI3K/Akt/mTOR and MAPK/ERK signaling pathways, driving both muscle hypertrophy and hyperplasia. Because it lacks the tripeptide Gly-Pro-Glu at the N-terminus, it cannot bind to IGFBPs that normally sequester ~98% of circulating IGF-1. This means the entire administered dose remains bioavailable. The very short half-life confines its activity to the local injection site, where it stimulates satellite cell proliferation and differentiation, protein synthesis, and nutrient uptake in the targeted muscle tissue.
Molecular data
- Type
- Truncated IGF-1 analog
- Half-life
- 20-30 minutes
Indications
What the research community uses this compound for, with self-reported effectiveness.
Muscle Growth
Localized Hypertrophy
Most effectiveSite-specific muscle growth via direct intramuscular injection into target muscle post-workout.
Hyperplasia
EffectiveStimulates satellite cell proliferation and differentiation, potentially creating new muscle fibers.
Recovery
EffectiveAccelerates local tissue recovery in the injected muscle group after training.
Tissue Repair
Local Tissue Repair
ModeratePromotes repair and regeneration at the injection site through IGF-1R activation.
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Injectable
Intramuscular injection directly into the target muscle immediately post-workout. The extremely short half-life means timing and site selection are critical. Consume fast carbohydrates after injection to mitigate hypoglycemia risk.
| Protocol | Dose | Frequency | Route / duration |
|---|---|---|---|
| Beginner Protocol | 20-30mcg | Post-workout, injected into trained muscle | IM (site-specific) |
| Intermediate | 30-50mcg | Post-workout, injected into trained muscle | IM (site-specific) |
| Advanced | 50mcg | Post-workout, split across multiple trained muscles | IM (site-specific) |
Preparation
You will need
- IGF-1 DES lyophilized powder
- Bacteriostatic water or 0.6% acetic acid
- Insulin syringes (29-31 gauge)
- Alcohol swabs
Steps
- Allow vial to reach room temperature (15-30 min)
- Sanitize rubber stopper with alcohol swab
- Calculate desired concentration (e.g., 1mg in 1mL = 1000mcg/mL)
- Inject diluent slowly along the vial wall
- Gently swirl -- do not shake
- Allow 2-5 minutes for complete dissolution
- Store reconstituted solution at 2-8C
- Use within 7 days when reconstituted with BAC water
- Acetic acid reconstitution extends stability
Work out the water volume and syringe units in the reconstitution calculator →
Interactions
Pairwise interactions with other compounds you might be cycling — the same data behind the cycle builder's safety check.
Insulin
AvoidBoth lower blood glucose. Combining IGF-1 DES with exogenous insulin significantly increases hypoglycemia risk.
IGF-1 LR3
MonitorDo not stack with IGF-1 DES. Both are IGF-1 analogs acting on the same receptor. Choose one or the other based on whether you want systemic (LR3) or localized (DES) effects.
Human Growth Hormone
SynergisticHGH raises baseline IGF-1 levels; adding IGF-1 DES post-workout provides a localized anabolic spike on top of elevated systemic IGF-1. Use with caution and monitor blood glucose.
Testosterone
SynergisticTestosterone increases IGF-1 receptor density and satellite cell number, amplifying the local effects of IGF-1 DES at the injection site.
Timeline
Typical week-by-week effects reported in clinical and observational data.
- Immediately post-injection
Localized muscle pump and fullness in the injected muscle within minutes; possible mild hypoglycemia
- Week 1-2
Noticeable pump and fullness in targeted muscles on training days; localized soreness at injection site
- Week 3-4
Visible improvements in targeted muscle size and shape; enhanced recovery between sessions
- Post-cycle
Effects diminish rapidly due to the short-acting nature; structural gains from hyperplasia may persist
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Hypoglycemia -- consume carbohydrates after injection
- Localized swelling and soreness at injection site
- Increased pump in targeted muscles
- Mild lightheadedness shortly after injection
Stop signs — stop and seek advice
- Severe or recurring hypoglycemia despite carbohydrate intake
- Disproportionate or asymmetric muscle growth
- Unusual growths, lumps, or rapid mole changes
- Persistent pain, redness, or infection at injection site
- Signs of systemic IGF-1 excess (jaw growth, organ enlargement)
Contraindications
- Not approved for human use -- research chemical only
- Cancer history or active malignancy (IGF-1 promotes cell proliferation)
- Diabetes or impaired glucose regulation
- WADA prohibited substance -- causes failed drug tests
Monitoring
- Consume 20-40g fast carbohydrates immediately after each injection
- Monitor blood glucose, especially during the first week
- Rotate injection sites to avoid localized fibrosis
- Limit cycles to 4-6 weeks with equal off-time
- Watch for disproportionate growth in frequently targeted muscles
Quality checks
What a legitimate product looks like, what should give pause, and what should make you stop.
Good signs
- HPLC purity >95%
- Mass spectrometry confirmation of truncated sequence
- Cold storage maintained (-20C lyophilized)
- Certificate of analysis from reputable source
Warning signs
- Research chemical only -- never approved for human use
- No human clinical trials exist
- Extremely short half-life requires precise timing
Stop signs — don't use
- Hypoglycemia risk -- blood sugar can drop rapidly after injection
- Potential for disproportionate muscle growth with repeated site-specific use
- Black market quality varies -- degraded product is common
- Cancer proliferation concern -- elevated IGF-1 activity promotes cell growth
References
Primary literature and clinical-trial data informing this entry.
The isolation and characterization of a naturally occurring truncated form of IGF-I in human brain
Sara VR, Carlsson-Skwirut C, Andersson C, Hall E, Sjogren B, Holmgren A, Jornvall H · Biochemical and Biophysical Research Communications · 1986
First identification and characterization of Des(1-3) IGF-1 as a naturally occurring truncated form of IGF-1 in human brain tissue, establishing that the N-terminal tripeptide deletion occurs endogenously.
Des(1-3)IGF-I: A truncated form of insulin-like growth factor-I that has greatly enhanced activity in promoting growth
Francis GL, Ross M, Ballard FJ, Milner SJ, Senn C, McNeil KA, Wallace JC, King R, Wells JR · Journal of Molecular Endocrinology · 1992
Des(1-3) IGF-1 demonstrated approximately 10-fold greater potency than intact IGF-1 in stimulating protein synthesis and cell proliferation, directly attributable to its inability to bind IGF binding proteins.
Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats
Tomas FM, Knowles SE, Owens PC, Chandler CS, Francis GL, Read LC, Ballard FJ · Biochemical Journal · 1992
Des(1-3) IGF-1 and LR3-IGF-1 were significantly more potent than native IGF-1 in reversing dexamethasone-induced muscle wasting in rats, with truncated and modified variants showing superior anabolic activity.
Circulating Insulin-like Growth Factor-I Concentrations and Risk of 30 Cancers: Prospective Analyses in UK Biobank
Murphy N, Knuppel A, Papadimitriou N, Martin RM, Tsilidis KK, Brennan P et al. · Cancer Research · 2020
Higher circulating IGF-1 associated with increased risks of colorectal, breast, prostate, and thyroid cancers in >395,000 UK Biobank participants, underscoring the cancer risk of sustained IGF-1 pathway activation.
Last updated . How this page was sourced is described in the methodology.